Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hildegard Sourgens"'
Autor:
Tim Hardman, Henri Caplain, Sylvie Rottey, Desiree Douglas, Steffan Stringer, Hildegard Sourgens
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
The second biennial conference of the European Federation for Exploratory Medicines Development (EUFEMED) was the result of a continued effort of EUFEMED to gather all stakeholders of exploratory clinical drug development to evaluate and discuss rece
Externí odkaz:
https://doaj.org/article/b186555598ff4addad28a3fec300aaad
Autor:
Kerstin Breithaupt-Grögler, Tim Hardman, Jan de Hoon, Yves Donazzolo, Sylvie Rottey, Hildegard Sourgens, Steffan Stringer
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
The European Federation for Exploratory Medicines Development (EUFEMED) organized a meeting in Leuven, Belgium entitled ‘The new FIH EMA guideline: Disruptive or constructive?’ to provide a forum for stakeholders to discuss the guideline’s oper
Externí odkaz:
https://doaj.org/article/b23e4873d6a34cf49989b280af3ddd46
Autor:
Luc Van Bortel, Hildegard Sourgens, Kerstin Breithaupt-Grögler, Henri Caplain, Yves Donazzolo, Ingrid Klingmann, Michael Hammond, Timothy C. Hardman, Steffan Stringer, Jan de Hoon
Publikováno v:
Frontiers in Pharmacology, Vol 8 (2018)
The first formal conference of the EUropean Federation for Exploratory MEdicines Development (EUFEMED) held in London was the result of a collaborative effort of its founding associations: the Association for Applied Human Pharmacology (AGAH; Germany
Externí odkaz:
https://doaj.org/article/e8d56503f6a649c0a713009e2c78b9b5
Autor:
Hildegard Sourgens, Katharina Erb-Zohar, Gerd Mikus, Frank Donath, Kerstin Breithaupt-Groegler, Stephanie Plassmann, Jens Rengelshausen, Georg Wensing, Timothy C. Hardman
Publikováno v:
Therapeutic Innovation & Regulatory Science
Purpose A discussion forum was hosted by the Association for Applied Human Pharmacology (AGAH e.V.) to critically debate how to interpret and optimise the Investigator’s Brochure (IB) for meaningful risk assessment of early clinical trials. Materia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::371232e0b364d853672206a9bd809a26
http://europepmc.org/articles/PMC7857342
http://europepmc.org/articles/PMC7857342
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Purpose To collect information on unintended drug exposure during pregnancy in early clinical drug development. Materials and methods Questionnaire mailed in autumn 2015 to members of human pharmacology societies in Europe for anonymous responses via
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc2587b687614f404e58bbebe21e5f08
https://doi.org/10.5414/cp203788
https://doi.org/10.5414/cp203788
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Purpose To collect information on the use of integrated protocols in early clinical medicines development. Materials and methods The questionnaire was mailed in fall 2014 to members of human pharmacology societies in Europe for anonymous responses vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfafdbefbafabf2eb4009abab7bbee41
https://doi.org/10.5414/cp203206
https://doi.org/10.5414/cp203206
Autor:
Karin Goehler, Thomas Sudhop, Martin Coenen, Klaus Peter Kammerer, Klaus Francke, Georg Wensing, Hildegard Sourgens, Jens Rengelshausen, Frank Donath, Mario Iovino, Kerstin Breithaupt-Groegler, Reinhard Schinzel, Gerd Mikus, Christoph Coch, Katharina Erb-Zohar
Publikováno v:
European Journal of Clinical Pharmacology
Introduction/Methods A discussion forum was hosted by the German not-for-profit Association for Applied Human Pharmacology (AGAH e.V.) to critically review key eligibility criteria and stopping rules for clinical trials with healthy subjects, enrolli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feabe534c46e9ba3d2232d9f80e5e871
http://europepmc.org/articles/PMC5350217
http://europepmc.org/articles/PMC5350217
Autor:
Sylvie Rottey, Hildegard Sourgens, Desiree Douglas, Steffan Stringer, Henri Caplain, Timothy C. Hardman
Publikováno v:
Frontiers in Pharmacology
FRONTIERS IN PHARMACOLOGY
Frontiers in Pharmacology, Vol 10 (2019)
FRONTIERS IN PHARMACOLOGY
Frontiers in Pharmacology, Vol 10 (2019)
The second biennial conference of the European Federation for Exploratory Medicines Development (EUFEMED) was the result of a continued effort of EUFEMED to gather all stakeholders of exploratory clinical drug development to evaluate and discuss rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdc529704b5eba0a101d919ab0125a33
https://doi.org/10.3389/fphar.2019.01377
https://doi.org/10.3389/fphar.2019.01377
Autor:
Kerstin Breithaupt-Grögler, Timothy C. Hardman, Luc Van Bortel, Henri Caplain, Ingrid Klingmann, Michael Hammond, Hildegard Sourgens, Yves Donazzolo, Steffan Stringer, Jan de Hoon
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 8 (2018)
Frontiers in Pharmacology, Vol 8 (2018)
The first formal conference of the EUropean Federation for Exploratory MEdicines Development (EUFEMED) held in London was the result of a collaborative effort of its founding associations: the Association for Applied Human Pharmacology (AGAH; Germany
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1387331cc4f884942900a2ff348ace33
https://doi.org/10.3389/fphar.2017.00901
https://doi.org/10.3389/fphar.2017.00901
Publikováno v:
The Journal of Clinical Pharmacology. 38:373-381
In vitro and animal experiments have characterized KA 672-HCl as a potent functional antagonist of excitatory amino acid-induced convulsions and mortality. In receptor-binding studies, the compound displayed high affinities to several serotoninergic,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0924a6f30a576d3911b71778472a2c
https://doi.org/10.1002/j.1552-4604.1998.tb04438.x
https://doi.org/10.1002/j.1552-4604.1998.tb04438.x